A phase 1 dose-escalation and pharmacokinetic (PK) study of a novel spectrum-selective kinase inhibitor (SSKI), XL647, in patients with advanced solid malignancies. 17th EORTC/AACR/NCI International Conference on Molecular Targets and Cancer Therapeutics Wakelee, H., Adjei, A. A., Halsey, J., Lensing, J., Dugay, J., Hanson, L., Reid, J., Hutchison, S., Piens, J., Sikic, B. I. AMER ASSOC CANCER RESEARCH. 2005: 9029S–9029S

View details for Web of Science ID 000234382700263